Who We Are 

President & CEO - Partner

Stephen created BusStim out of the need for an entrepreneurial implementation to leverage these former big pharma executives' ecosystem and rich academia innovation here in NY, NJ, and PA. He is a long-term entrepreneur with over 30 years of experience. At a young age, he left a successful career at Johnson & Johnson as Cost Accounting Manager to start ACCURATE Information Systems Inc. a cutting-edge Information Technology Consulting firm.

He built a management team around a group of Ph.D. level, highly qualified software engineers, electrical engineers, and computer experts from Bell Labs and academia. ACCURATE unleashed their skills and knowledge to work on some highly innovative and highprofile projects. Steve and his team built ACCURATE to an $18 Million – 110 employee organization. For over 10 years, he teamed with other entrepreneurs to design/refine business models and structure alliances to start or expand their businesses.

A few years ago, he observed the state of the industry in Big Pharma country and decided to pull together an organization to stimulate the situation with the creation of BusStim. As a result of his many years of experience in several successful ventures and startups, Stephen has the passion, energy level, consulting industry experience, and creativity to build a vision for a team to follow.

Vice President and Chief Medical Officer - Partner

Dr. Greene is the Founder and Lead Consultant of Dagphamed. He was the Executive Vice President, Chief Scientific Officer at IKARIA from May 2014 to October 2015, before which he served as our Executive Vice President, Research and Development. Before joining us, from April 2009 to April 2010, Dr. Greene served as Senior Vice President and Senior Scientific Advisor at Sanofi-aventis, a global pharmaceutical company.

From August 2006 to March 2009, Dr. Greene served as Senior Vice President and Chief Medical Officer of the US business at Sanofi-aventis. From June 2003 to July 2006, Dr. Greene served as Vice President and Head of Corporate Regulatory Development at Sanofi-aventis. Dr. Greene was Executive Vice President of Clinical Sciences and Product Development at Merck Research Laboratories and Corporate Officer of Merck, Inc., a global pharmaceutical company, from May 2000 to January 2003.

Dr. Greene also was a member of the US Food and Drug Administration’s Endocrinologic and Metabolic Drug Advisory Committee from 1988 to 1994 and acted as Chairman of the Advisory Committee from 1990 to 1994. From 1986 to 2000, Dr. Greene was Professor of Internal Medicine, Director of the Michigan Diabetes Research and Training Center, and Chief, Division of Endocrinology & Metabolism at the University of Michigan School of Medicine. Dr. Greene holds an MD from the Johns Hopkins School of Medicine and an AB from Princeton University.

Ph.D. Vice President of Business Development & Alliance Management - Partner Dr. Thomas Argentieri is a Pharma and Biotech Executive with over 30 years of experience in academic, Pharma and Biotech R&D. Dr. Argentieri received his Ph.D. in pharmacology from the New Jersey Medical School (Rutgers University) focusing on ion channel biophysics and received post-doctoral training at the University of Pennsylvania. He spent several years as a research assistant professor at the University of Pennsylvania's department of medicine studying mechanisms of cardiac arrhythmias.

From there Dr. Argentieri was Section Head at Berlex Pharmaceuticals, helping to build and lead their antiarrhythmic and antihypertensive drug discovery efforts putting 2 drugs into the clinic. Seven years later he was recruited by Wyeth  Pharmaceuticals to direct their Urologic Disorders division where he oversaw the development of novel ion channel modulators and beta-3 adrenergic receptor agonists for the treatment of overactive bladder. During this period he authored over 70 peer-reviewed manuscripts, review articles, and book chapters, and was awarded 10 patents.

After over 20 years in R&D, he transitioned into business development performing in-licensing and out-licensing activities for the pharmaceutical and Biotech industries and conducted numerous deals on both the buy and sell-side. Dr. Argentieri is the owner and founder of BioSense Solutions, a company that provides scientific evaluation, market research, licensing, and business development expertise to the pharmaceutical and biotech industries. He currently serves on the editorial boards of the Journal of Pharmacology and Experimental Therapeutics (JPET) and the Open Pharmacology Journal.

Vice President Business Development & Commercialization - Partner Paul is a business leader and advisor with over 40 years of pharmaceutical research, marketing, new product development, commercialization, and business development experience. He is presently a Partner in BusStim, a virtual biotech accelerator, and owner of PJ BioPharma Solutions.

Paul was previously with Pfizer for nearly 30 years where his last position was VP, Early Commercial Development, where he was responsible for Pfizer’s Primary Care Division pipeline products and business development deals.

Paul began his career as an organic chemist at Schering, then Merck. After several years he joined Pfizer in US Marketing. Over the years he was responsible for Pfizer's new product commercialization, business development, and global marketing across many therapeutic areas including infectious disease, allergy, respiratory, neuroscience, and pain. Paul contributed to many of Pfizer’s successful licensing and acquisition deals. Later in his career, he led Pfizer’s cardiovascular franchise, including new products and global marketing. Many of Paul’s products became billion-dollar sellers including Zyrtec, Aricept, Diflucan, Champix, Geodon, Norvasc, and Lipitor. Just before leaving Pfizer Paul was co-leader on Eliquis, now one of Pfizer’s most successful products, selling over $5 billion/year with partner BMS.

Paul now uses his pharmaceutical development and deal-making experience to help biotechs maximize their product or company value to potential investors or pharma partners. He aided Excaliard in achieving acquisition by Pfizer. He has consulted for Aralez, Oligomerix, Saniona, and MAPS Public Benefit Corp. As a partner in BusStim, he is an advisor to Shifa Biomedical and 4 other biotechs. He is on the Board of Arkay Therapeutics.

Paul is active in his community as VP of Ortley Beach Voters and Taxpayers Assn, and Trustee of Friends of Ortley Beach, both focused on re-building his NJ shore community following damage from Superstorm Sandy. He also enjoys kayaking, bicycling and snow skiing.

Jerome is an Inventor and Chief Executive Officer of TheraSyn an IP holding company with his 85 granted and published patents.  Currently Emeritus Professor of Pharmacy at the University of Buffalo, NY, Prof Schentag has 40+ years of US and Global Translational Pharmacology expertise in Infectious Diseases, Critical Care, Sepsis, Metabolic Syndrome, and oncology. 

He developed and applied PK/PD modeling to antimicrobials over many years, eventually leading to these principles as a core principle of antibiotic development and marketing.  He has deep expertise in drug delivery systems, starting with the invention of the SmartPill, a medical device for diagnosis of GI tract malfunction and the predicate device for the characterization of the ileal Brake. He is the Co-inventor of Brake™, the first oral mimetic of RYGB Bariatric surgery and its associated cure of Type 2 Diabetes and Metabolic syndrome.  Dr. Schentag and colleagues have used the teachings of the SmartPill to invent a practical means of oral absorption and intracellular delivery of peptides, proteins and other macromolecules. This is the only known means of converting these otherwise injectable biologicals into a practical form for regular use.  . He is also a co-inventor on microbiome delivery systems to the colon and ileum vaccination for both infectious disease and immuno-oncology.   Prof Schentag’s research in immuno-oncology has recently characterized Myocarditis associated with checkpoint inhibitors in oncology, and he is currently studying Myocarditis associated with Covid-19 and Covid-19 vaccines.  Further information on Patents is available at http://www.schentag.com/

Dr Schentag’s entrepreneurial experience comprises several private equity investments and exit

transactions across a broad spectrum in healthcare. He obtained his Pharm.D. at the Philadelphia College of Pharmacy & Science, followed by postdoctoral fellowship training in the clinical applications of  Pharmacokinetics and Pharmacodynamics at the University of Buffalo. 

Vice President of Contracts & Legal - General Counsel & Partner

Gregory has a diverse background. Graduating from the Bronx High School of Science, then going on to Columbia College to receive a BA in Political Science.  He next graduated from Harvard Law School in 1975, where he received his JD.  Over the last 35+ years, he has refined his legal expertise, such that it includes solving complex financial and legal problems in the areas of taxation, finance, business law, real estate development, contract negotiations, litigation and human resource management.  As an attorney and counselor at law, Gregory prides himself on the ability to bring diverse personalities and often adversarial factions together to achieve a common goal.  Gregory started as a prosecutor in the New York County District Attorneys’ Office.  This was followed by five years at the Federal Reserve Bank of New York.  He has also been an Administrative Law Judge for New York City business and excise taxation, as well as a General Counsel for multiple not-for-profit corporations, along with their for-profit housing subsidiary corporations, affiliated limited partnerships, and limited liability companies.